Hepatitis B has been clinically cured these people surface antigens can be transnegative

Professor Gao Zhiliang, Director of the Infection Department of the Third Hospital affiliated with Sun Yat-sen University, said that the department's follow-up clinic established a large data specimen resource bank and a cohort study for hepatitis B patientsSince the I-cure program was launched in 2015, the clinical cure rate for hepatitis B patients selected for the program has been as high as one thirdWHO data show that there are approximately 257 million people living with hepatitis B virus worldwide, and 887,000 people die each year from hepatitis BOne of the most important characteristics of the clinical cure of hepatitis B is the trans-feminine surface antigen of hepatitis Baccording to the 2015 guidelines for the prevention and treatment of chronic hepatitis B, for some suitable patients to pursue the clinical cure of chronic hepatitis B as far as possible, i.e., the continuous virological response after discontinuation of treatment, the disappearance of surface antigen HBsAg and accompanied by ALT (one of the indicators of liver function) and improved liver histology lesionsGao Zhiliang pointed out that long-term treatment of nucleoside antiviral drugs such as Endikawe or tinofory, although the continuous control of the disease, but within five years, about 7% of patients will develop liver cancer, if the patient has cirrhosis, the proportion of up to 17%and if the surface antigen transfeminine, the probability of liver cancer is only 0.8%, even if the patient has cirrhosis, only 6% of the probability will develop liver cancerTherefore, the realization of clinical cure is of great significance to hepatitis B patientsto achieve the "operational goal" of clinical cure, oral antiviral drugs alone can not be" aloneIn patients with hepatitis B with oral antiviral drugs, if the surface antigen is less than 1500 units, long-acting interferon can be added for treatment, and 30% of patients can be removed"Big Three Yang" should not pursue "clinical cure"however, some patients are not suitable for the pursuit of "clinical cure of hepatitis B"experts stressed that e antigen-positive chronic hepatitis B patients, also known as the "Big Three Yang" patients, because at this time the virus in the liver a large number of generation, if long-acting interferon treatment, the probability of obtaining a clinical cure for hepatitis B is lowpatients who have achieved "clinical cure" can stop taking drugs under certain conditions, and the probability of recurrence after discontinuation is not highIf the surface antigen quantification is examined at intervals of one month, the value of two consecutive times is less than 0.05, the patient can discontinue the drugHowever, after discontinuation of the drug is recommended to follow up once every six months to prevent recurrenceGao Zhiliang's team also found that many patients who received clinical cures for hepatitis B were relatively young Doctors speculate that young patients than older patients infected with hepatitis B virus for a shorter time, the human body's immune function is also better, after receiving interferon treatment, their immune function can be more fully mobilized to launch an "attack", so as to have a better chance of achieving clinical cure.